EXCEL PROJECT 3
chandlerrosas
JohnsonJohnson.xlsxCompany Information
| ACCT 370 Excel Project | ||
| Johnson & Johnson | ||
| Company Information | ||
| Company Name | Johnson & Johnson | |
| Ticker Symbol | JNJ | |
| Industry | Pharmaceuticals, Consumer products, Medical Devices | |
| Products and Services Offered | Beauty, Over The Counter Pharmaceuticals, Baby Care, Oral Care, Women's Health, Wound Care | |
| Immunology, Infectious Disease Vaccines, Neuroscience, Oncology, Cardiovascular Metabolic Diseases | ||
| Orthopaedic, Surgery, Cardiovascular, Diabetes care, Vision Care | ||
| Major Competitors | Pfizer, Merck, Proctor & Gamble, Bristol Myers Squibb, Unilever | |
Historical Income Statements
| JOHNSON & JOHNSON AND SUBSIDIARIES | ||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||
| At December 30, 2018 and December 30, 2017 | ||||
| (Dollars in Millions) (Note 1) | ||||
| $2,018.00 | $2,017.00 | $2,016.00 | ||
| Net earnings | $15,297.00 | $1,300.00 | $16,540.00 | |
| Other comprehensive income (loss), net of tax | ||||
| Foreign currency translation | -$1,518.00 | $1,696.00 | -$612.00 | |
| Securities: (1) | ||||
| Unrealized holding gain (loss) arising during period | -$1.00 | $159.00 | -$52.00 | |
| Reclassifications to earnings | $1.00 | -$338.00 | -$141.00 | |
| Net change | $0.00 | -$179.00 | -$193.00 | |
| Employee benefit plans: | ||||
| Prior service credit (cost), net of amortization | -$44.00 | $2.00 | $21.00 | |
| Gain (loss), net of amortization | -$56.00 | $29.00 | -$862.00 | |
| Effect of exchange rates | $92.00 | -$201.00 | $159.00 | |
| Net change | -$8.00 | -$170.00 | -$682.00 | |
| Derivatives & hedges: | ||||
| Unrealized gain (loss) arising during period | -$73.00 | -$4.00 | -$359.00 | |
| Reclassifications to earnings | -$192.00 | $359.00 | $110.00 | |
| Net change | -$265.00 | $355.00 | -$249.00 | |
| Other comprehensive income (loss) | -$1,791.00 | $1,702.00 | -$1,736.00 | |
| Comprehensive income | $13,506.00 | $3,002.00 | $14,804.00 | |
Historical Balance Sheets
| JOHNSON & JOHNSON AND SUBSIDIARIES | ||||
| CONSOLIDATED BALANCE SHEETS | ||||
| At December 30, 2018 and December 30, 2017 | ||||
| (Dollars in Millions Except Share and Per Share Amounts) (Note 1) | ||||
| 2018 | 2017 | 2016 | ||
| Assets | ||||
| Current assets | ||||
| Cash and cash equivalents (Notes 1 and 2) | $ 18,107.00 | $ 17,824.00 | $ 18,972.00 | |
| Marketable securities (Notes 1 and 2) | $ 1,580.00 | $ 472.00 | $ 22,935.00 | |
| Accounts receivable trade, less allowances for doubtful accounts $248 (2017, $291) | $ 14,098.00 | $ 13,490.00 | $ 11,699.00 | |
| Inventories (Notes 1 and 3) | $ 8,599.00 | $ 8,765.00 | $ 8,144.00 | |
| Prepaid expenses and other receivables | $ 2,699.00 | $ 2,537.00 | $ 3,282.00 | |
| Assets held for sale (Note 20) | $ 950.00 | $ - 0 | $ - 0 | |
| Total current assets | $ 46,033.00 | $ 43,088.00 | $ 65,032.00 | |
| Property, plant and equipment, net (Notes 1 and 4) | $ 17,035.00 | $ 17,005.00 | $ 15,912.00 | |
| Intangible assets, net (Notes 1 and 5) | $ 47,611.00 | $ 53,228.00 | $ 26,876.00 | |
| Goodwill (Notes 1 and 5) | $ 30,453.00 | $ 31,906.00 | $ 22,805.00 | |
| Deferred taxes on income (Note 8) | $ 7,640.00 | $ 7,105.00 | $ 6,148.00 | |
| Other assets | $ 4,182.00 | $ 4,971.00 | $ 4,435.00 | |
| Total assets | $ 152,954.00 | $ 157,303.00 | $ 141,208.00 | |
| Liabilities and Shareholders’ Equity | ||||
| Current liabilities | ||||
| Loans and notes payable (Note 7) | $ 2,796.00 | $ 3,906.00 | $ 4,684.00 | |
| Accounts payable | $ 7,537.00 | $ 7,310.00 | $ 6,918.00 | |
| Accrued liabilities | $ 7,601.00 | $ 7,304.00 | $ 5,635.00 | |
| Accrued rebates, returns and promotions | $ 9,380.00 | $ 7,210.00 | $ 5,403.00 | |
| Accrued compensation and employee related obligations | $ 3,098.00 | $ 2,953.00 | $ 2,676.00 | |
| Accrued taxes on income (Note 8) | $ 818.00 | $ 1,854.00 | $ 971.00 | |
| Total current liabilities | $ 31,230.00 | $ 30,537.00 | $ 26,287.00 | |
| Long-term debt (Note 7) | $ 27,684.00 | $ 30,675.00 | $ 22,442.00 | |
| Deferred taxes on income (Note 8) | $ 7,506.00 | $ 8,368.00 | $ 2,910.00 | |
| Employee related obligations (Notes 9 and 10) | $ 9,951.00 | $ 10,074.00 | $ 9,615.00 | |
| Long-term taxes payable (Note 8) | $ 8,242.00 | $ 8,472.00 | $ 9,536.00 | |
| Other liabilities | $ 8,589.00 | $ 9,017.00 | $ - 0 | |
| Total liabilities | $ 93,202.00 | $ 97,143.00 | $ 70,790.00 | |
| Shareholders’ equity | ||||
| Preferred stock — without par value (authorized and unissued 2,000,000 shares) | $ - 0 | $ - 0 | $ - 0 | |
| Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | $ 3,120.00 | $ 3,120.00 | $ 3,120.00 | |
| Accumulated other comprehensive income (loss) (Note 13) | $ -15,222.00 | $ -13,199.00 | $ -14,901.00 | |
| Retained earnings | $ 106,216.00 | $ 101,793.00 | $ 110,551.00 | |
| $ 94,114.00 | $ 91,714.00 | $ 98,770.00 | ||
| Less: common stock held in treasury, at cost (Note 12) (457,519,000 shares and 437,318,000 shares) | $ 34,362.00 | $ 31,554.00 | $ 28,352.00 | |
| Total shareholders’ equity | $ 59,752.00 | $ 60,160.00 | $ 70,418.00 | |
| Total liabilities and shareholders’ equity | $ 152,954.00 | $ 157,303.00 | $ 141,208.00 | |
Historical Statement of Cash Fl
| JOHNSON & JOHNSON AND SUBSIDIARIES | ||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
| At December 30, 2018 and December 30, 2017 | ||||
| (Dollars in Millions) (Note 1) | ||||
| 2018 | 2017 | 2016 | ||
| Cash flows from operating activities | ||||
| Net earnings | $ 15,297.00 | $ 1,300.00 | $ 16,540.00 | |
| Adjustments to reconcile net earnings to cash flows from operating activities: | ||||
| Depreciation and amortization of property and intangibles | $ 6,929.00 | $ 5,642.00 | $ 3,754.00 | |
| Stock based compensation | $ 978.00 | $ 962.00 | $ 878.00 | |
| Asset write-downs | $ 1,258.00 | $ 795.00 | $ 283.00 | |
| Gain on sale of assets/businesses | $ -1,217.00 | $ -1,307.00 | $ -563.00 | |
| Deferred tax provision | $ -1,016.00 | $ 2,406.00 | $ -341.00 | |
| Accounts receivable allowances | $ -31.00 | $ 17.00 | $ -11.00 | |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: | ||||
| Increase in accounts receivable | $ -1,185.00 | $ -633.00 | $ -1,065.00 | |
| (Increase)/Decrease in inventories | $ -644.00 | $ 581.00 | $ -249.00 | |
| Increase in accounts payable and accrued liabilities | $ 3,951.00 | $ 2,725.00 | $ 656.00 | |
| Increase in other current and non-current assets | $ -275.00 | $ -411.00 | $ -529.00 | |
| (Decrease)/Increase in other current and non-current liabilities | $ -1,844.00 | $ 8,979.00 | $ -586.00 | |
| Net cash flows from operating activities | $ 22,201.00 | $ 21,056.00 | $ 18,767.00 | |
| Cash flows from investing activities | ||||
| Additions to property, plant and equipment | $ -3,670.00 | $ -3,279.00 | $ -3,226.00 | |
| Proceeds from the disposal of assets/businesses, net | $ 3,203.00 | $ 1,832.00 | $ 1,267.00 | |
| Acquisitions, net of cash acquired (Note 20) | $ -899.00 | $ -35,151.00 | $ -4,509.00 | |
| Purchases of investments | $ -5,626.00 | $ -6,153.00 | $ -33,950.00 | |
| Sales of investments | $ 4,289.00 | $ 28,117.00 | $ 35,780.00 | |
| Other (primarily intangibles) | $ -464.00 | $ -234.00 | $ -123.00 | |
| Net cash used by investing activities | $ -3,167.00 | $ -14,868.00 | $ -4,761.00 | |
| Cash flows from financing activities | ||||
| Dividends to shareholders | $ -9,494.00 | $ -8,943.00 | $ -8,621.00 | |
| Repurchase of common stock | $ -5,868.00 | $ -6,358.00 | $ -8,979.00 | |
| Proceeds from short-term debt | $ 80.00 | $ 869.00 | $ 111.00 | |
| Retirement of short-term debt | $ -2,479.00 | $ -1,330.00 | $ -2,017.00 | |
| Proceeds from long-term debt, net of issuance costs | $ 5.00 | $ 8,992.00 | $ 12,004.00 | |
| Retirement of long-term debt | $ -1,555.00 | $ -1,777.00 | $ -2,223.00 | |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | $ 949.00 | $ 1,062.00 | $ 1,189.00 | |
| Other | $ -148.00 | $ -188.00 | $ -15.00 | |
| Net cash used by financing activities | $ -18,510.00 | $ -7,673.00 | $ -8,551.00 | |
| Effect of exchange rate changes on cash and cash equivalents | $ -241.00 | $ 337.00 | $ -215.00 | |
| Increase/(Decrease) in cash and cash equivalents | $ 283.00 | $ -1,148.00 | $ 5,240.00 | |
| Cash and cash equivalents, beginning of year (Note 1) | $ 17,824.00 | $ 18,972.00 | $ 13,732.00 | |
| Cash and cash equivalents, end of year (Note 1) | $ 18,107.00 | $ 17,824.00 | $ 18,972.00 | |
| Supplemental cash flow data | ||||
| Cash paid during the year for: | ||||
| Interest | $ 1,049.00 | $ 960.00 | $ 730.00 | |
| Interest, net of amount capitalized | $ 963.00 | $ 866.00 | $ 628.00 | |
| Income taxes | $ 4,570.00 | $ 3,312.00 | $ 2,843.00 | |
Uniliver Inc.Sta
| Uniliver Consolidated Income Statement - EUR (€) € in Millions | |||
| At December 30, 2018 and December 30, 2017 | |||
| 12 Months Ended | |||
| Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
| Profit or loss [abstract] | |||
| Turnover | $ 51,980.00 | $ 50,982.00 | $ 53,715.00 |
| Operating profit | $ 8,708.00 | $ 12,639.00 | $ 8,957.00 |
| Which includes non-underlying item credits/(charges) of | $ -1,239.00 | $ 3,176.00 | $ -543.00 |
| Net finance costs | $ -627.00 | $ -608.00 | $ -1,004.00 |
| Finance income | $ 224.00 | $ 135.00 | $ 157.00 |
| Finance costs | $ -821.00 | $ -718.00 | $ -683.00 |
| Pensions and similar obligations | $ -30.00 | $ -25.00 | $ -96.00 |
| Net finance cost non-underlying items | $ -382.00 | ||
| Non-underlying item net monetary gain/(loss) arising from hyperinflationary economies | $ 32.00 | $ 122.00 | |
| Share of net profit/(loss) of joint ventures and associates | $ 176.00 | $ 185.00 | $ 155.00 |
| Which includes non-underlying item credits/(charges) of | $ 3.00 | $ 32.00 | |
| Other income/(loss) from non-current investments and associates | $ 22.00 | $ 18.00 | |
| Profit before taxation | $ 8,289.00 | $ 12,360.00 | $ 8,126.00 |
| Taxation | $ -2,263.00 | $ -2,572.00 | $ -1,670.00 |
| Which includes tax impact of non-underlying items of | $ 113.00 | $ -288.00 | $ 655.00 |
| Net profit | $ 6,026.00 | $ 9,788.00 | $ 6,456.00 |
| Attributable to: | |||
| Non-controlling interests | $ 401.00 | $ 419.00 | $ 433.00 |
| Shareholders' equity | $ 5,625.00 | $ 9,369.00 | $ 6,023.00 |
| Combined earnings per share | |||
| Basic earnings per share (€) | $ 2.15 | $ 3.49 | $ 2.15 |
| Diluted earnings per share (€) | $ 2.14 | $ 3.48 | $ 2.14 |
uniliver BAL
| Uniliver Consolidated Balance Sheet - EUR (€) € in Millions | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
| At December 30, 2018 and December 30, 2017 | |||
| Non-current assets | |||
| Goodwill | $ 18,067.00 | $ 17,341.00 | $ 16,881.00 |
| Intangible assets | $ 12,962.00 | $ 12,152.00 | $ 11,520.00 |
| Property, plant and equipment | $ 12,062.00 | $ 12,088.00 | $ 12,270.00 |
| Pension asset for funded schemes in surplus | $ 2,422.00 | $ 1,728.00 | $ 2,173.00 |
| Deferred tax assets | $ 1,336.00 | $ 1,152.00 | $ 1,118.00 |
| Financial assets | $ 874.00 | $ 642.00 | $ 675.00 |
| Other non-current assets | $ 653.00 | $ 530.00 | $ 441.00 |
| Total non-current assets | $ 48,376.00 | $ 45,633.00 | $ 45,078.00 |
| Current assets | |||
| Inventories | $ 4,164.00 | $ 4,301.00 | $ 3,962.00 |
| Trade and other current receivables | $ 6,695.00 | $ 6,482.00 | $ 5,219.00 |
| Current tax assets | $ 397.00 | $ 472.00 | $ 488.00 |
| Cash and cash equivalents | $ 4,185.00 | $ 3,230.00 | $ 3,317.00 |
| Other financial assets | $ 907.00 | $ 874.00 | $ 770.00 |
| Assets held for sale | $ 82.00 | $ 119.00 | $ 3,224.00 |
| Current assets | $ 16,430.00 | $ 15,478.00 | $ 16,980.00 |
| Total assets | $ 64,806.00 | $ 61,111.00 | $ 62,058.00 |
| Current liabilities | |||
| Financial liabilities | $ 4,691.00 | $ 3,613.00 | $ 8,378.00 |
| Trade payables and other current liabilities | $ 14,768.00 | $ 14,457.00 | $ 13,426.00 |
| Current tax liabilities | $ 898.00 | $ 1,445.00 | $ 1,088.00 |
| Provisions | $ 620.00 | $ 624.00 | $ 525.00 |
| Liabilities held for sale | $ 1.00 | $ 11.00 | $ 170.00 |
| Total current liabilities | $ 20,978.00 | $ 20,150.00 | $ 23,587.00 |
| Non-current liabilities | |||
| Financial liabilities | $ 23,566.00 | $ 23,125.00 | $ 18,039.00 |
| Non-current tax liabilities | $ 182.00 | $ 174.00 | $ 118.00 |
| Pensions and post-retirement healthcare liabilities: | |||
| Funded schemes in deficit | $ 1,157.00 | $ 1,209.00 | $ 1,225.00 |
| Unfunded schemes | $ 1,461.00 | $ 1,393.00 | $ 1,509.00 |
| Provisions | $ 664.00 | $ 697.00 | $ 794.00 |
| Deferred tax liabilities | $ 2,573.00 | $ 1,900.00 | $ 1,888.00 |
| Other non-current liabilities | $ 339.00 | $ 346.00 | $ 700.00 |
| Total non current liabilities | $ 29,942.00 | $ 28,844.00 | $ 24,273.00 |
| Total liabilities | $ 50,920.00 | $ 48,994.00 | $ 47,860.00 |
| Shareholders' equity | |||
| Called up share capital | $ 420.00 | $ 464.00 | $ 484.00 |
| Share premium account | $ 134.00 | $ 129.00 | $ 130.00 |
| Other reserves | $ -5,574.00 | $ -15,218.00 | $ -13,587.00 |
| Retained profit | $ 18,212.00 | $ 26,022.00 | $ 26,413.00 |
| Total equity attributable to owners of parent | $ 13,192.00 | $ 11,397.00 | $ 13,440.00 |
| Non-controlling interests | $ 694.00 | $ 720.00 | $ 758.00 |
| Total equity | $ 13,886.00 | $ 12,117.00 | $ 14,198.00 |
| Total liabilities and equity | $ 64,806.00 | $ 61,111.00 | $ 62,058.00 |
Uniliver. Cashflow
| Uniliver Consolidated Cash Flow Statement - EUR (€) € in Millions | 12 Months Ended | ||
| Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
| Statement of cash flows [abstract] | |||
| Net profit | $ 6,026.00 | $ 9,788.00 | $ 6,456.00 |
| Taxation | $ 2,263.00 | $ 2,572.00 | $ 1,670.00 |
| Share of net (profit)/loss of joint ventures/associates and other (income)/loss from non-current investments and associates | $ -176.00 | $ -207.00 | $ -173.00 |
| Net monetary (gain)/loss arising from hyperinflationary economies | $ -32.00 | $ -122.00 | |
| Net finance costs | $ 627.00 | $ 608.00 | $ 1,004.00 |
| Operating profit | $ 8,708.00 | $ 12,639.00 | $ 8,957.00 |
| Depreciation, amortisation and impairment | $ 1,982.00 | $ 2,216.00 | $ 2,025.00 |
| Changes in working capital: | $ -9.00 | $ -793.00 | $ -68.00 |
| Inventories | $ 313.00 | $ -471.00 | $ -104.00 |
| Trade and other receivables | $ -445.00 | $ -1,298.00 | $ -506.00 |
| Trade payables and other liabilities | $ 123.00 | $ 976.00 | $ 542.00 |
| Pensions and similar obligations less payments | $ -260.00 | $ -128.00 | $ -904.00 |
| Provisions less payments | $ 7.00 | $ 55.00 | $ 200.00 |
| Elimination of (profits)/losses on disposals | $ 60.00 | $ -4,313.00 | $ -298.00 |
| Non-cash charge for share-based compensation | $ 151.00 | $ 196.00 | $ 284.00 |
| Other adjustments | $ 2.00 | $ -260.00 | $ -153.00 |
| Cash flow from operating activities | $ 10,641.00 | $ 9,612.00 | $ 10,043.00 |
| Income tax paid | $ -2,532.00 | $ -2,294.00 | $ -2,164.00 |
| Net cash flow from operating activities | $ 8,109.00 | $ 7,318.00 | $ 7,879.00 |
| Interest received | $ 146.00 | $ 110.00 | $ 154.00 |
| Purchase of intangible assets | $ -210.00 | $ -203.00 | $ -158.00 |
| Purchase of property, plant and equipment | $ -1,316.00 | $ -1,329.00 | $ -1,509.00 |
| Disposal of property, plant and equipment | $ 97.00 | $ 108.00 | $ 46.00 |
| Acquisition of businesses and investments in joint ventures and associates | $ -1,122.00 | $ -1,336.00 | $ -4,896.00 |
| Disposal of businesses, joint ventures and associates | $ 177.00 | $ 7,093.00 | $ 561.00 |
| Acquisition of other non-current investments | $ -160.00 | $ -94.00 | $ -317.00 |
| Disposal of other non-current investments | $ 55.00 | $ 151.00 | $ 251.00 |
| Dividends from joint ventures, associates and other non-current investments | $ 164.00 | $ 154.00 | $ 138.00 |
| (Purchase)/sale of financial assets | $ -68.00 | $ -10.00 | $ -149.00 |
| Net cash flow (used in)/from investing activities | $ -2,237.00 | $ 4,644.00 | $ -5,879.00 |
| Dividends paid on ordinary share capital | $ -4,209.00 | $ -4,066.00 | $ -3,916.00 |
| Interest paid | $ -694.00 | $ -571.00 | $ -574.00 |
| Net change in short-term borrowings | $ 337.00 | $ -4,026.00 | $ 2,695.00 |
| Additional financial liabilities | $ 5,911.00 | $ 10,595.00 | $ 8,851.00 |
| Repayment of financial liabilities | $ -4,912.00 | $ -6,594.00 | $ -2,604.00 |
| Capital element of lease payments | $ -435.00 | $ -481.00 | $ -497.00 |
| Buyback of preference shares | $ -448.00 | ||
| Repurchase of shares | $ -6,020.00 | $ -5,014.00 | |
| Other movements on treasury shares | $ -201.00 | $ -257.00 | $ -204.00 |
| Other financing activities | $ -464.00 | $ -693.00 | $ -309.00 |
| Net cash flow (used in)/from financing activities | $ -4,667.00 | $ -12,113.00 | $ -2,020.00 |
| Net increase/(decrease) in cash and cash equivalents | $ 1,205.00 | $ -151.00 | $ -20.00 |
| Cash and cash equivalents at the beginning of the year | $ 3,090.00 | $ 3,169.00 | $ 3,198.00 |
| Effect of foreign exchange rate changes | $ -179.00 | $ 72.00 | $ -9.00 |
| Cash and cash equivalents at the end of the year | $ 4,116.00 | $ 3,090.00 | $ 3,169.00 |
Pfizer Inc.Statement
| PFIZER CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||
| At December 30, 2018 and December 30, 2017 | |||
| US$ in millions | 2018 | 2017 | 2016 |
| 12 months ended: | 12/31/18 | 12/31/17 | 12/31/16 |
| Revenues | $ 53,647.00 | $ 52,546.00 | $ 52,824.00 |
| Cost of sales | $ -11,248.00 | $ -11,240.00 | $ -12,329.00 |
| Gross profit | $ 42,399.00 | $ 41,306.00 | $ 40,495.00 |
| Selling, informational and administrative expenses | $ -14,455.00 | $ -14,784.00 | $ -14,837.00 |
| Research and development expenses | $ -8,006.00 | $ -7,657.00 | $ -7,872.00 |
| Amortization of intangible assets | $ -4,893.00 | $ -4,758.00 | $ -4,056.00 |
| Restructuring charges and certain acquisition-related costs | $ -1,044.00 | $ -487.00 | $ -1,724.00 |
| Operating income | $ 14,001.00 | $ 13,620.00 | $ 12,006.00 |
| Gain on completion of Consumer Healthcare JV transaction | $ - 0 | $ - 0 | $ - 0 |
| Interest income | $ 333.00 | $ 391.00 | $ 470.00 |
| Interest expense | $ -1,316.00 | $ -1,270.00 | $ -1,186.00 |
| Net interest expense | $ -983.00 | $ -879.00 | $ -716.00 |
| Foreign currency loss related to Venezuela | $ - 0 | $ - 0 | $ - 0 |
| Royalty-related income | $ 495.00 | $ 499.00 | $ 905.00 |
| Net gains on asset disposals | $ 71.00 | $ 343.00 | $ 171.00 |
| Net gains recognized during the period on equity securities | $ 586.00 | $ - 0 | $ - 0 |
| Net realized losses on sales of investments in debt securities | $ -141.00 | $ - 0 | $ - 0 |
| Income from collaborations, out-licensing arrangements and sales of compound/product rights | $ 488.00 | $ - 0 | $ - 0 |
| Net periodic benefit credits (costs) other than service costs | $ 288.00 | $ - 0 | $ - 0 |
| Certain legal matters, net | $ -157.00 | $ -240.00 | $ -510.00 |
| Certain asset impairments | $ -3,115.00 | $ -395.00 | $ -1,447.00 |
| Business and legal entity alignment costs | $ -4.00 | $ -71.00 | $ -261.00 |
| Net losses on early retirement of debt | $ -3.00 | $ -999.00 | $ -312.00 |
| GSK Consumer Healthcare JV equity method income | $ - 0 | $ - 0 | $ - 0 |
| Other, net | $ 359.00 | $ 427.00 | $ -1,485.00 |
| Other income (deductions), net | $ -2,116.00 | $ -1,315.00 | $ -3,655.00 |
| Income from continuing operations before (provision) benefit for taxes on income | $ 11,885.00 | $ 12,305.00 | $ 8,351.00 |
| (Provision) benefit for taxes on income | $ -706.00 | $ 9,048.00 | $ -1,122.00 |
| Income from continuing operations | $ 11,179.00 | $ 21,353.00 | $ 7,229.00 |
| Income (loss) from discontinued operations, net of tax | $ 9.00 | $ -1.00 | $ 16.00 |
| Gain (loss) on disposal of discontinued operations, net of tax | $ - 0 | $ 3.00 | $ 1.00 |
| Discontinued operations, net of tax | $ 9.00 | $ 2.00 | $ 17.00 |
| Net income before allocation to noncontrolling interests | $ 11,188.00 | $ 21,355.00 | $ 7,246.00 |
| Net income attributable to noncontrolling interests | $ -35.00 | $ -47.00 | $ -31.00 |
| Net income attributable to Pfizer Inc. | $ 11,153.00 | $ 21,308.00 | $ 7,215.00 |
| Preferred stock dividends, net of tax | $ -1.00 | $ -1.00 | $ -1.00 |
| Net income attributable to Pfizer Inc. common shareholders | $ 11,152.00 | $ 21,307.00 | $ 7,214.00 |
| Based on: 10-K (filing date: 2020-02-27), 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-29). |
Pfizer Balance Sheet
| Consolidated Balance Sheet | |||
| 2018 | Nov-17 | Nov-16 | |
| PFIZER CONSOLIDATED BALANCE SHEETS | |||
| At December 30, 2018 and December 30, 2017 | |||
| EQUITIES AND LIABILITIES | 2018 | 2017 | 2016 |
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | $ 29.84 | $ 29.84 | $ 29.84 |
| Preference Share Capital | $ - 0 | $ - 0 | $ - 0 |
| Total Share Capital | $ 29.84 | $ 29.84 | $ 29.84 |
| Revaluation Reserves | $ - 0 | $ - 0 | $ - 0 |
| Reserves and Surplus | $ 871.25 | $ 619.88 | $ 375.89 |
| Total Reserves and Surplus | $ 871.25 | $ 619.88 | $ 375.89 |
| Money Received Against Share Warrants | $ - 0 | $ - 0 | $ - 0 |
| Employees Stock Options | $ - 0 | $ - 0 | $ - 0 |
| Total Shareholders Funds | $ 901.09 | $ 649.72 | $ 405.73 |
| Preference Shares Issued By Subsidiary Companies | $ - 0 | $ - 0 | $ - 0 |
| Equity Share Application Money | $ - 0 | $ - 0 | $ - 0 |
| Preference Share Application Money | $ - 0 | $ - 0 | $ - 0 |
| Share Capital Suspense | $ - 0 | $ - 0 | $ - 0 |
| Hybrid/Debt/Other Securities | $ - 0 | $ - 0 | $ - 0 |
| Statutory Consumer Reserves | $ - 0 | $ - 0 | $ - 0 |
| Special Appropriation Towards Project Cost | $ - 0 | $ - 0 | $ - 0 |
| Service Line Contribution From Consumers | $ - 0 | $ - 0 | $ - 0 |
| Government/Other Grants | $ - 0 | $ - 0 | $ - 0 |
| Minority Interest | $ - 0 | $ - 0 | $ - 0 |
| Policy Holders Funds | $ - 0 | $ - 0 | $ - 0 |
| Group Share In Joint Ventures | $ - 0 | $ - 0 | $ - 0 |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | $ - 0 | $ - 0 | $ - 0 |
| Deferred Tax Liabilities [Net] | $ 3.01 | $ 4.50 | $ 2.26 |
| Other Long Term Liabilities | $ - 0 | $ - 0 | $ - 0 |
| Long Term Provisions | $ - 0 | $ - 0 | $ - 0 |
| Total Non-Current Liabilities | $ 3.01 | $ 4.50 | $ 2.26 |
| Foreign Currency Monetary Item Translation Difference A/C | $ - 0 | $ - 0 | $ - 0 |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | $ - 0 | $ - 0 | $ - 0 |
| Trade Payables | $ 108.18 | $ 92.05 | $ 129.08 |
| Other Current Liabilities | $ 14.50 | $ 14.55 | $ 16.39 |
| Short Term Provisions | $ 73.87 | $ 111.14 | $ 94.69 |
| Total Current Liabilities | $ 196.55 | $ 217.74 | $ 240.16 |
| Total Capital And Liabilities | $ 1,100.65 | $ 871.97 | $ 648.15 |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | $ 50.61 | $ 60.01 | $ 65.00 |
| Intangible Assets | $ 0.16 | $ 0.16 | $ 0.16 |
| Capital Work-In-Progress | $ 32.30 | $ 10.24 | $ 1.60 |
| Intangible Assets Under Development | $ - 0 | $ - 0 | $ - 0 |
| Other Assets | $ - 0 | $ - 0 | $ - 0 |
| Cnstruction Stores | $ - 0 | $ - 0 | $ - 0 |
| Mining Development Expenditure | $ - 0 | $ - 0 | $ - 0 |
| Assets Held For Sale | $ - 0 | $ - 0 | $ - 0 |
| Fixed Assets | $ 83.06 | $ 70.41 | $ 66.76 |
| Non-Current Investments | $ 0.50 | $ 0.50 | $ - 0 |
| Deferred Tax Assets [Net] | $ 25.68 | $ 17.48 | $ 16.62 |
| Long Term Loans And Advances | $ - 0 | $ - 0 | $ - 0 |
| Other Non-Current Assets | $ - 0 | $ 2.93 | $ 13.34 |
| Total Non-Current Assets | $ 109.25 | $ 91.32 | $ 96.72 |
| Minority Interest | $ - 0 | $ - 0 | $ - 0 |
| Group Share In Joint Ventures | $ - 0 | $ - 0 | $ - 0 |
| Foreign Currency Monetary Item Translation Difference A/C | $ - 0 | $ - 0 | $ - 0 |
| CURRENT ASSETS | |||
| Current Investments | $ - 0 | $ - 0 | $ - 0 |
| Inventories | $ 124.99 | $ 95.85 | $ 99.31 |
| Trade Receivables | $ 60.31 | $ 61.69 | $ 69.48 |
| Cash And Cash Equivalents | $ 543.65 | $ 479.91 | $ 306.94 |
| Short Term Loans And Advances | $ 261.96 | $ 142.69 | $ 70.90 |
| OtherCurrentAssets | $ 0.50 | $ 0.50 | $ 4.80 |
| Total Current Assets | $ 991.41 | $ 780.64 | $ 551.43 |
| Total Assets | $ 1,100.65 | $ 871.97 | $ 648.15 |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | $ 68.69 | $ 105.72 | $ 59.34 |
| Other Earnings | $ - 0 | $ - 0 | $ - 0 |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | $ 19.11 | $ 19.11 | $ 19.11 |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | $ - 0 | $ - 0 | $ - 0 |
| Non-Current Investments Unquoted Book Value | $ 0.50 | $ 0.50 | $ - 0 |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | $ - 0 | $ - 0 | $ - 0 |
| Current Investments Unquoted Book Value | $ - 0 | $ - 0 | $ - 0 |
Pfizer Cash Flow Sta
| PFIZER CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
| At December 30, 2018 and December 30, 2017 | |||
| US$ in millions | 2018 | 2017 | 2016 |
| 12 months ended: | 12/31/18 | 12/31/17 | 12/31/16 |
| Net income before allocation to noncontrolling interests | $ 11,188.00 | $ 21,355.00 | $ 7,246.00 |
| Depreciation and amortization | $ 6,384.00 | $ 6,269.00 | $ 5,757.00 |
| Asset write-offs and impairments | $ 3,398.00 | $ 634.00 | $ 1,613.00 |
| Foreign currency loss related to Venezuela | $ - 0 | $ - 0 | $ - 0 |
| Loss on disposal of discontinued operations | $ - 0 | $ - 0 | $ - 0 |
| TCJA impact | $ -596.00 | $ -10,660.00 | $ - 0 |
| Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed | $ - 0 | $ - 0 | $ - 0 |
| Deferred taxes from continuing operations | $ -2,205.00 | $ -2,410.00 | $ -700.00 |
| Deferred taxes from discontinued operations | $ - 0 | $ - 0 | $ - 0 |
| Share-based compensation expense | $ 949.00 | $ 840.00 | $ 691.00 |
| Benefit plan contributions in excess of expense | $ -1,095.00 | $ -961.00 | $ -712.00 |
| Other adjustments, net | $ -1,270.00 | $ 107.00 | $ 1,921.00 |
| Trade accounts receivable | $ -644.00 | $ 259.00 | $ -134.00 |
| Inventories | $ -717.00 | $ -357.00 | $ 365.00 |
| Other assets | $ -16.00 | $ -31.00 | $ -60.00 |
| Trade accounts payable | $ 431.00 | $ 46.00 | $ 871.00 |
| Other liabilities | $ 98.00 | $ -67.00 | $ -223.00 |
| Other tax accounts, net | $ -78.00 | $ 1,446.00 | $ -734.00 |
| Changes in assets and liabilities, net of acquisitions and divestitures | $ -926.00 | $ 1,296.00 | $ 85.00 |
| Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities | $ 4,639.00 | $ -4,885.00 | $ 8,655.00 |
| Net cash provided by operating activities | $ 15,827.00 | $ 16,470.00 | $ 15,901.00 |
| Purchases of property, plant and equipment | $ -2,042.00 | $ -1,956.00 | $ -1,823.00 |
| Purchases of short-term investments | $ -11,677.00 | $ -14,596.00 | $ -15,957.00 |
| Proceeds from redemptions/sales of short-term investments | $ 17,581.00 | $ 10,307.00 | $ 29,436.00 |
| Net (purchases of) proceeds from redemptions/sales of short-term investments with original maturities of three months or less | $ -3,917.00 | $ 2,058.00 | $ -4,218.00 |
| Purchases of long-term investments | $ -1,797.00 | $ -3,537.00 | $ -8,011.00 |
| Proceeds from redemptions/sales of long-term investments | $ 6,244.00 | $ 3,594.00 | $ 11,254.00 |
| Acquisitions of businesses, net of cash acquired | $ - 0 | $ -1,000.00 | $ -18,368.00 |
| Acquisitions of intangible assets | $ -154.00 | $ -261.00 | $ -176.00 |
| Other investing activities, net | $ 287.00 | $ 650.00 | $ 52.00 |
| Net cash (used in) provided by investing activities | $ 4,525.00 | $ -4,741.00 | $ -7,811.00 |
| Proceeds from short-term borrowings | $ 3,711.00 | $ 8,464.00 | $ 7,472.00 |
| Principal payments on short-term borrowings | $ -4,437.00 | $ -9,990.00 | $ -5,102.00 |
| Net proceeds from (payments on) short-term borrowings with original maturities of three months or less | $ -1,617.00 | $ 1,401.00 | $ -3,084.00 |
| Proceeds from issuances of long-term debt | $ 4,974.00 | $ 5,274.00 | $ 10,976.00 |
| Principal payments on long-term debt | $ -3,566.00 | $ -6,154.00 | $ -7,689.00 |
| Purchases of common stock | $ -12,198.00 | $ -5,000.00 | $ -5,000.00 |
| Cash dividends paid | $ -7,978.00 | $ -7,659.00 | $ -7,317.00 |
| Proceeds from exercise of stock options | $ 1,259.00 | $ 862.00 | $ 1,019.00 |
| Other financing activities, net | $ -589.00 | $ -233.00 | $ -196.00 |
| Net cash used in financing activities | $ -20,441.00 | $ -13,035.00 | $ -8,921.00 |
| Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents | $ -116.00 | $ 53.00 | $ -215.00 |
| Net increase (decrease) in cash and cash equivalents and restricted cash and cash equivalents | $ -205.00 | $ -1,253.00 | $ -1,046.00 |
| Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period | $ 1,430.00 | $ 2,595.00 | $ 3,641.00 |
| Cash and cash equivalents and restricted cash and cash equivalents, at end of period | $ 1,225.00 | $ 1,342.00 | $ 2,595.00 |
| Based on: 10-K (filing date: 2020-02-27), 10-K (filing date: 2019-02-28), 10-K (filing date: 2018-02-22), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-29). |
Fanacial statement Analysis
| JOHNSON & JOHNSON AND SUBSIDIARIES | COMPETITORS RATIO ANALYSIS | |||||||||
| Uniliver | Pfizer | Industry Average | ||||||||
| Ratios | 2018 | 2017 | 2016 | 2018 | 2017 | 2016 | 2018 | 2017 | 2016 | |
| Liquidity | ||||||||||
| Current ratio | 1.47 | 1.41 | 2.47 | 0.78 | 0.77 | 0.72 | 5.04 | 3.59 | 2.30 | 2.06 |
| Quick Ratio | 4.62 | 4.86 | 5.06 | 0.58 | 0.55 | 0.55 | 0.79 | 0.79 | 0.70 | 2.06 |
| Leverage Ratios | - 0 | |||||||||
| Debt to total assets ratio | 0.61 | 0.62 | 0.50 | 0.79 | 0.80 | 0.77 | 0.18 | 0.25 | 0.37 | 0.54 |
| Debt to equity ratio | 1.56 | 1.61 | 1.01 | 3.67 | 4.04 | 3.37 | 0.22 | 0.34 | 0.60 | 1.82 |
| Long-term debt to equity | 0.46 | 0.51 | 0.32 | 0.46 | 0.47 | 0.39 | 0.00 | 0.01 | 0.00 | 0.29 |
| Times interest earned ratio | 166.27 | - 6.47 | 104.03 | 20.67 | 29.50 | 18.77 | - 319.66 | - 454.36 | - 233.74 | - 75.00 |
| Activity Ratios | - 0 | |||||||||
| Inventory Turnover | 1.78 | 0.15 | 2.03 | 12.48 | 11.85 | 13.56 | - 89.99 | - 117.27 | - 124.15 | - 32.17 |
| Fixed asset turnover | 0.90 | 0.08 | 1.04 | 1.07 | 1.12 | 1.19 | 4.91 | 5.75 | 5.46 | 2.39 |
| Total asset turnover | 0.10 | 0.01 | 0.12 | 0.80 | 0.83 | 0.87 | 48.74 | 60.26 | 81.50 | 21.47 |
| Account receivable turnover | 1.09 | 0.10 | 1.41 | 7.76 | 7.87 | 10.29 | 97.68 | 108.49 | 171.10 | 45.09 |
| Average collection period | 3.36 | 37.88 | 2.58 | 47.01 | 46.41 | 35.46 | 5.78 | 5.21 | 3.30 | 20.78 |
| Profitaibilty Ratio | - 0 | |||||||||
| Gross profit margin | 0.44 | - 5.74 | 0.51 | 0.92 | 0.92 | 0.93 | 1.21 | 1.21 | 1.23 | 0.18 |
| Operating profit margin | 0.88 | 2.31 | 0.90 | 0.80 | 0.83 | 0.87 | 0.26 | 0.26 | 0.23 | 0.82 |
| Net profit margin | 0.88 | 2.31 | 0.90 | 0.13 | 0.21 | 0.14 | 10.13 | 24.44 | 11.13 | 5.59 |
| Return on total assets | 0.33 | 0.03 | 0.25 | 0.09 | 0.16 | 0.10 | 48.74 | 60.26 | 81.50 | 21.28 |
| Return on stockholders Equity | 0.23 | 0.05 | 0.21 | 1.07 | 1.04 | 1.07 | 59.54 | 80.87 | 130.19 | 30.48 |
| Earning per share | 4.42 | 20.04 | 4.76 | 2.15 | 3.15 | 4.15 | 12.41 | 32.86 | 17.82 | 11.31 |
| Price Earning Ratio | 19.57 | 401.60 | 22.63 | 1.07 | 1.04 | 1.07 | 4.80 | 2.46 | 7.31 | 51.28 |
